Obesity ETF (SLIM)
| Bid | - |
| Market Cap | 11.34M |
| AUM | 11.63M |
| NAV | 34.12 |
| EPS (ttm) | 0.00 |
| PE Ratio (ttm) | n/a |
| Shares Out | 340.96K |
| Inception Date | Jun 8, 2016 |
| Ask | - |
| Volume | 6.31K |
| Open | 35.36 |
| Previous Close | 36.16 |
| Day's Range | 33.00 - 36.62 |
| 52-Week Range | 33.00 - 43.40 |
| Holdings | 0 |
| Expense Ratio | 0.35% |
About SLIM
The investment seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. The fund invests at least 80% of its net assets in the stocks that comprise the Solactive Obesity Index. It is non-diversified.
Top Sectors
| Sector | Weight % |
|---|---|
| Healthcare | 91.86% |
| Consumer Defensive | 4.25% |
| Consumer Cyclical | 3.89% |
Dividends Dividend Yield 0.59%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 19, 2019 | $0.0054 | Dec 26, 2019 |
| Sep 30, 2019 | $0.0520 | Oct 4, 2019 |
| Jun 28, 2019 | $0.0710 | Jul 5, 2019 |
| Mar 29, 2019 | $0.0917 | Apr 4, 2019 |
| Dec 20, 2018 | $0.0068 | Dec 27, 2018 |
1 month ago · seekingalpha.com
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity DisorderRhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel...
